Governments, payers and antibiotic makers will be watching closely as the UK tests the world's first subscription-style payment model in which payments delinked from sales volume are used to incentivize pharmaceutical companies to develop new drugs for resistant infections.
The pilot program, first announced in July, will be led by the National Institute for Health and Care Excellence (NICE),...








